R.R. Donnelley & Sons Co. (RRD) Tops Q3 EPS by 7c;Sees FY13 EPS at Lower-End
Tweet
Share
E-mailGet Alerts RRD Hot Sheet
Price: $10.84 --0%
Financial Fact:
Dividends declared per common share: 0.78
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Dividends declared per common share: 0.78
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
R.R. Donnelley & Sons Co. (NASDAQ: RRD) reported Q3 EPS of $0.51, $0.07 better than the analyst estimate of $0.44. Revenue for the quarter came in at $2.51 billion versus the consensus estimate of $2.58 billion.
R.R. Donnelley & Sons Co. sees FY2012 revenue of $10.1-10.2 billion, versus the consensus of $10.37 billion. Sees EPS at lower-end of prior outlook.
For earnings history and earnings-related data on R.R. Donnelley & Sons Co. (RRD) click here.
R.R. Donnelley & Sons Co. sees FY2012 revenue of $10.1-10.2 billion, versus the consensus of $10.37 billion. Sees EPS at lower-end of prior outlook.
For earnings history and earnings-related data on R.R. Donnelley & Sons Co. (RRD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies sees a buying opportunity in this S&P 500 sector
- Candel Therapeutics, Inc. (CADL) Misses Q2 EPS by 29c
- CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
